The Omega-3 Market in 2026

When people search for an omega business plan, they are almost always costing out one thing: a brand built on EPA and DHA — the two long-chain omega-3 fatty acids that come from fish oil, krill oil or algal oil. That is a real, mature, and unusually well-documented category, which is good news for anyone writing a plan, because it means a lender or investor can check your numbers against published data in about four minutes.

The global omega-3 supplements market was estimated at $7.68 billion in 2024 and is projected to reach $12.89 billion by 2030, a compound annual growth rate of 9.1% across 2025 to 2030, according to Grand View Research. Within that total, the fish oil segment held the largest revenue share at 61.5% in 2024 — a number worth internalising, because it tells you that roughly six out of every ten dollars in this category still flow to conventional marine oil, not to the krill and algal products that dominate the press coverage.

Forecasts diverge past 2030, and you should know that before an investor points it out. Grand View's $12.89 billion by 2030 sits alongside a DataM Intelligence projection of $17.08 billion by 2032. These are not contradictions so much as different segment definitions — some houses count only finished supplements, others fold in fortified food and pharmaceutical-grade concentrates. Pick one house view, cite it, and say why. Plans that quote three different market sizes on three different pages get read as careless.

That last comparison is the most useful single fact on this page, and almost nobody writing about this category draws it out. The ingredient market — actual fish oil, sold by the tonne — is worth about $2.39 billion in 2025 and growing at roughly 5.9%, per Fact.MR. The finished supplement market is worth over three times that and growing at nearly double the rate. The gap between those two numbers is the brand margin, and it is the entire reason a person with no factory can build a profitable omega-3 business. You are not competing with DSM or Croda. You are buying from them, or from someone who buys from them, and selling trust.

Geographically, the United States is the largest single national market, and it is led by premium brands rather than by price fighters, per Intellectual Market Insights. That matters for positioning. In a category where the incumbents are premium, a new entrant undercutting on price is fighting on the one axis where a 40-year-old brand with amortised tooling will always win. The openings are elsewhere: format (emulsions, gummies, high-concentration single-capsule doses), source (algal for the vegan buyer), and evidence (published TOTOX and contaminant data on the label rather than in a PDF nobody opens).

A quick note on who you are actually up against. Nordic Naturals markets Ultimate Omega as the number-one-selling omega-3 in the US, on purity and science-based formulation. Carlson Labs is a long-established premium fish oil house with estimated 2024 revenue of roughly $200 million. Nature's Bounty, founded in 1971, plays the broad mass-market range. OmegaBrite holds a narrow niche in high-purity pharmaceutical-grade EPA for mood and inflammation. Barlean's built its position almost entirely on solving taste, with flavoured emulsions. Four of those five won by picking one attribute and owning it. None won by being a slightly cheaper generic fish oil, and your plan should not propose to.

One structural tailwind is worth naming because it changes your supplier conversation. Algal oil is plant-based, rich in DHA, free of the fishy taste that drives a large share of category churn, and carries no marine contaminant load to test around. It is also more expensive per gram of DHA. If your plan proposes algal, the investor question is not "is vegan growing" — it is "can you hold a price premium large enough to cover a more expensive oil, and for how long before the price of algal DHA falls and your premium goes with it".

Funding an Omega-3 Brand: SBA and UK Routes

Before the cost table, deal with the funding route, because the route determines which cost table you need. An omega-3 business that outsources manufacturing is a working-capital problem. An omega-3 business that manufactures is a capital-equipment problem. Lenders treat those completely differently.

In the US, the relevant classification is NAICS 325412 if you manufacture finished supplements, or NAICS 424490 if you are a brand owner distributing product made by someone else. Founders routinely file under the manufacturing code because it sounds more substantial, then get asked for equipment schedules and facility leases they do not have.

The SBA 7(a) programme is the realistic debt route for a US omega-3 brand with some trading history. In fiscal year 2025 the SBA guaranteed approximately 77,600 loans totalling $37 billion, up from 70,242 loans and $31.1 billion in FY2024, with an average loan size of $477,571, according to Crestmont Capital's analysis of SBA lending data. That average is roughly three to twenty-five times what a private-label omega-3 launch actually needs — you are a small borrower in a programme built around larger ones, and small borrowers get scrutinised harder per dollar, not less.

If you are manufacturing, the picture is more encouraging. The SBA reported over 1,120 7(a) loans to manufacturers totalling $677 million approved since 20 January 2025, a 74% increase in approvals against the comparable prior period, per the U.S. Small Business Administration. Softgel encapsulation equipment is exactly the kind of collateralisable, resaleable asset that makes a 7(a) manufacturing application work. Inventory of a perishable oil is exactly the kind of asset that does not.

In the UK, the honest answer is that most first-time omega-3 founders are not bank-fundable at launch and should stop trying to be. The Start Up Loans scheme from the British Business Bank lends £500 to £25,000 per director at a fixed 6% per annum over one to five years, unsecured, with free mentoring attached. A two-director company can therefore assemble £50,000, which covers a first private-label run and a modest launch budget but will not fund tooling, stability testing and a paid-acquisition push simultaneously. Beyond that, the realistic routes are SEIS for an equity raise — genuinely well-suited to a consumer brand with a defensible formulation angle — or supplier credit, which in this category is more available than founders expect once you have placed two clean orders.

One funding structure worth modelling explicitly: a purchase-order or inventory facility rather than a term loan. Your cash cycle is the problem — you pay a contract manufacturer 50% on order and the balance before shipment, then wait sixty to ninety days for retail to pay. That gap, not the launch cost, is what kills omega-3 brands in year two, and a monthly cash bridge through the first two production runs is worth more to a lender than another page of growth charts.

What a First Run Really Costs

Published startup costs for a supplement brand range from $2,000 to $250,000, and every one of those figures is defensible, which is why the ranges are useless until you decode them. Matsun Nutrition puts a private-label launch at $2,000 to $10,000 — true, if you take a stock formulation at a 100–500 unit MOQ and do your own branding. Openloop Health puts it at $10,000 to $100,000 — also true, one tier up. The spread is not disagreement; it is three different businesses. For the case most searchers mean — a custom-formulated private-label omega-3 brand with one SKU, third-party certification, and enough launch budget to find out whether the thing sells — we model $18,000 to $145,000 in the US, or £14,000 to £116,000 in the UK.

Per-bottle softgel pricing per Build Your Own Brand's private-label pricing guide. Formulation, stability, tooling, CoA and label figures per Inventory Ready's supplement manufacturer pricing and MOQ guide. Certification range per Nutrasource's IFOS programme. Admin and marketing lines are Avvale estimates from client engagements.

The MOQ decision is the whole cost model

Most custom manufacturers set a minimum order quantity of 2,500 to 5,000 units per SKU for capsules, tablets or powder pouches. Private-label programmes — where you take an existing formulation and put your label on it — go as low as 100 to 500 units. Moving from a 500-unit private-label run to a 5,000-unit custom run typically cuts your per-bottle cost by 30% to 45%.

That discount is real and it is a trap. Fish oil oxidises. Every month a bottle sits in a warehouse its peroxide and anisidine values climb, and a product that tested beautifully on fill day can fail a retailer's incoming spec eighteen months later. If your honest forecast is 250 bottles a month and you buy 5,000 units for the price break, you have bought twenty months of stock for a continuously degrading product. The saving is nominal; the write-off is real. Buy MOQ against your shelf life and forecast, not against the quote sheet.

Founders also consistently miss the recurring costs hidden inside a one-off-looking table. Certificate of Analysis testing runs $500 to $2,000 per batch, not per lifetime. Stability testing repeats when you change the formulation, the supplier or the packaging. Purity certification renews. In our research and content engagements, the most common correction we make to a founder's cost model is moving four or five lines from the one-off column to the recurring column — which usually knocks 6 to 11 points off the modelled year-one net margin.

• Decide manufacture vs. private label before you cost anything — they are different businesses
• Size the first run against months of cover at your forecast, not against the price break
• Move CoA, stability and certification into the recurring column
• Budget the launch marketing line honestly, or don't place the production order
• Carry a 15% contingency; first runs almost always need a second label revision

Three Omega-3 Businesses, Not One

The reason cost guidance in this category is such a mess is that "omega-3 business" describes three different companies with different capital structures, different customers and different failure modes. Pick one in the first paragraph of your executive summary. A plan that hedges between them reads as a founder who has not decided, and no lender funds an undecided founder.

Most omega-3 plans that cross our desk are Model A described using Model B's language, usually because the founder toured a contract manufacturer's facility and came away describing its capacity as though it were an asset on their own balance sheet. It is not. If you are Model A, your assets are a formulation, a brand, a customer list and a supply agreement — build the plan around defending those four things.

Model B is worth understanding even if you will never be one, because it explains your cost floor. MarisOmega, Icelandirect, Matsun Nutrition and Fulfyld run on 22–40% margins, which means the price they quote you is not padded by much. When a founder tells us they will "negotiate the manufacturer down 30%", they are proposing that a business hand over most of its gross margin. It does not happen, and asking usually costs you flexibility on the things that do matter: run scheduling, MOQ tiering and payment terms.

Model C is where DSM, Croda International, GC Rieber and Omega Protein live. They set the price of the oil in your capsule, and that price moves with fish stocks, quota decisions and El Niño cycles. Even as a Model A brand, model a sensitivity on the oil input — a 20% swing in bulk oil cost is an ordinary year here.

Per-Bottle Economics and Why Order Two Matters

Supplement margins get quoted at 40% to 60%, and that figure gets copied between articles without anyone saying whether it is gross or net. It is gross, roughly, and only before customer acquisition. Model A omega-3 brands typically run 55% to 75% gross and land somewhere between 8% and 22% net once paid acquisition is honest. If your plan shows a 45% net margin in year one, the reader will assume you have not costed CAC, and they will be right.

Typical price points: DTC retail runs $24 to $52 for a 60–120 softgel bottle; Amazon sits lower at $18 to $38 because the comparison set there is dominated by low-concentration oils; wholesale into a retail door goes at about 50% of MSRP; and subscription usually carries a 15% discount off MSRP. Those four channels have completely different unit economics and should be four columns in your model, not one blended average.

Walk that through, because the arithmetic is the argument. A 60-softgel bottle of 1,000 mg concentrated fish oil lands at $2.90 COGS and sells DTC at $32.00. Gross profit is $29.10, or 91% — a number that makes founders euphoric and lenders suspicious. Deduct $4.20 for pick, pack and shipping, and $1.05 for payment processing, and contribution is $23.85. Now subtract a blended acquisition cost of $38.00. The first order is $14.15 underwater.

This is the central fact of the omega-3 business, and it is why the category's winners are subscription businesses wearing retail clothing. The account turns profitable on order two, and across a three-bottle first-year cohort it returns roughly $71.55 in contribution. Everything operational follows: reorder rate is your only real KPI, taste and reflux are churn drivers with a P&L line attached, and any tactic that lifts first-order volume while depressing reorder rate destroys the business while appearing to grow it.

Three levers move these numbers more than anything else you will do. Concentration: a 1,000 mg capsule at 30% EPA+DHA and one at 75% look identical on a shelf and cost materially different amounts to fill, and only the second lets you print a claim at a one-capsule dose — the single most consequential decision in the whole formulation, for reasons the next section explains. MOQ tier: the 30–45% per-bottle saving from moving up a tier is the biggest available margin improvement, bounded by shelf life. Oxidation-driven shrinkage: fish oil is a decaying asset, so model a write-off percentage on inventory held beyond your sell-through forecast. Most plans model zero, which is how a 22% net margin quietly becomes 11%.

Claims, Licences and the Rules That Set Your Dose

Here is the thing almost every omega-3 guide gets backwards. They tell you to formulate the product, then check the regulations. In this category the regulations set the formulation, because the health claim you want on the front of the bottle has a legally mandated minimum daily dose attached to it, and that dose determines your fill weight, which determines your COGS, which determines your price, which determines whether the business works. Claim first. Everything else follows.

United Kingdom

Omega-3 sold as a food supplement is regulated under food law by the Food Standards Agency. There is no product licence and no pre-approval — but there is also no safety net, and enforcement runs through local authority Trading Standards after you are already on shelf. Omega-3 sold as a prescription medicine falls to the MHRA instead, which is a different and far more expensive road; do not wander onto it accidentally by making a medicinal claim.

The GB-authorised health claims for EPA and DHA carry these mandatory daily doses, per the GB and EFSA authorised claims register:

Read that table as a pricing menu, because that is what it is. The 250 mg heart-function claim fits in one small capsule and costs almost nothing to support. The 3 g blood-pressure claim needs either a high-concentration oil or a four-capsule daily dose, both of which roughly triple your cost per day of use — and the consumer has to actually take four capsules a day for the claim to mean anything, which most will not.

The corresponding trap is well documented. Claims including "reduces inflammation", "boosts immunity", "prevents heart disease" and "essential for joint health" appear regularly on omega-3 products and are not authorised. A peer-reviewed compliance survey found 107 authorised claims across 59 supplements against nine unauthorised claims on nine products — a study of health-claim compliance on omega-3 food supplements. The more insidious failure is not the outright banned claim; it is the authorised claim printed on a product whose dose does not reach the threshold. If you see a standard single-capsule product carrying the blood pressure or triglyceride claim, the intake threshold is not being met, and that is a compliant-looking label that is not compliant.

For an upper bound: long-term supplemental intakes of EPA and DHA up to 5 g per day are considered safe for adults under the retained EFSA position. That number bounds the maximum defensible dose you can build a product around.

United States

The controlling regulation is 21 CFR Part 111, the dietary supplement current good manufacturing practice rule, published as a final rule on 25 June 2007. It applies to every domestic and foreign facility that manufactures, packages, labels or holds dietary supplements for sale in the US — the full text is on the eCFR, and the FDA publishes a Small Entity Compliance Guide which is genuinely readable and free.

Two clauses do most of the work in practice. §111.75 requires identity testing of incoming ingredients — you must verify that the drum labelled "anchovy oil, 30% EPA/DHA" contains what it says. §111.105 requires designated quality control personnel, an actual named person with authority to reject a batch. FDA findings are issued on a Form 483; leave those unaddressed and the next steps are a public warning letter and potentially an injunction closing the plant.

The point founders miss: using a compliant contract manufacturer does not transfer your liability. As the brand owner you remain responsible for the finished product, so diligence is not a formality — ask for the FDA facility registration number, ask when they were last inspected, and ask to see the 483s. A manufacturer who is uncomfortable with those three questions has answered them.

Separately, structure/function claims must be notified to FDA within 30 days of first marketing, with no fee. Disease claims convert your supplement into an unapproved drug — the most common enforcement trigger in this category, because omega-3's large genuine cardiovascular evidence base makes it unusually tempting to say the thing you are not allowed to say.

Canada

Canada is the jurisdiction most plans forget and the one that most rewards attention, because the pathway is cheap and the market is adjacent. Omega-3 and other essential fatty acid supplements require a Natural Product Number (NPN) from Health Canada before sale. Health Canada publishes a fish oil monograph — a pre-established standard defining acceptable ingredients, doses and claims.

If your product sits entirely inside that monograph it qualifies as a Class I application with a 60-day target review, typically 2 to 8 weeks in practice. Step outside the monograph and you are into Class II at 3 to 9 months, or Class III with a 180–210 day target that frequently runs 12 to 24 months in the real world. And critically: there is presently no Health Canada fee for submitting an NPN application. Your cost is regulatory consulting and evidence assembly, not government fees.

That asymmetry should shape your formulation. A product designed to fit the monograph opens Canada in under two months for the price of some paperwork. The same product with one clever off-monograph ingredient opens Canada in a year and a half. Put that trade-off in the plan explicitly — it is exactly the kind of commercial judgement an investor wants evidence you can make.

The voluntary standards that function as compulsory ones

No regulator requires third-party purity certification. Every serious retail buyer does, which makes it compulsory in the only sense that matters.

IFOS — International Fish Oil Standards, operated by Nutrasource and SGS — launched in 2004, certifies over 200 brands worldwide and has tested more than 15,000 product SKUs. It tests three things: active ingredient content (does the bottle contain the omega-3 the label claims), contaminants, and oxidative stability.

That third one is where the money is. IFOS measures peroxide value (primary oxidation) and anisidine value (secondary oxidation) and calculates TOTOX, the total oxidation value. Under GOED monograph limits TOTOX should sit below 26; premium products test under 10. IFOS also applies a PCB limit of 0.09 ppm total PCBs — half the level the EU permits.

Translate that into business terms and TOTOX stops being a quality badge and becomes a working-capital constraint. Your oil starts with a TOTOX value the day it is filled, and that value only goes up. If you fill at TOTOX 8 you have room to sit in a warehouse; if you fill at TOTOX 22 to save a few cents per bottle, you have bought stock that fails a premium retailer's spec within months. The incoming TOTOX you negotiate with your supplier is, functionally, the shelf life of your inventory — and therefore the maximum MOQ you can safely buy. No ranking page in this category makes that connection, and it is the single most useful thing an omega-3 founder can understand before placing a first order.

Five Mistakes That Kill Omega-3 Brands

The first mistake deserves the extra paragraph because it is unique to this category and almost never written about. A founder decides on a premium blood-pressure positioning, formulates a nice-looking 1,000 mg single capsule, prints the label, then discovers the blood pressure claim requires 3 g of EPA+DHA per day. Their capsule delivers perhaps 300 mg. To make the claim lawfully, the consumer must take ten capsules a day — which nobody does — or the founder needs a high-concentration oil and a redesigned capsule, meaning new tooling, a new stability study and a new print run. The failure traces entirely to sequencing: they formulated, then read the rules. Reverse the order and the problem disappears.

Sample Business Plan Preview

Here's a genuine extract from an omega-3 business plan written by our team, so you can see the level of specificity we work at:

Notice what that extract does that a generic plan does not. It names the dose and says why. It ties the dose to a specific authorised claim, the claim to a market-entry decision in another country, and the TOTOX spec to the size of the first production order. Every number is load-bearing and connected to another number. That is what an investor means by a "tight" plan, and it is what our bespoke plan service is built to produce.

What's in the Template

The omega business plan template is an editable Word document structured around the sections a lender or investor actually reads, with prompts written for this category rather than generic business-plan filler:

• Executive summary — with a prompt forcing you to declare Model A, B or C in the first paragraph
• Product and formulation — claim-first worksheet: pick the claim, derive the dose, derive the fill weight
• Market analysis — pre-populated with the Grand View and Fact.MR figures cited on this page, with space for your own segment work
• Competitive positioning — a grid for placing yourself against the premium incumbents on source, format, concentration and evidence
• Supply chain and manufacturing — contract manufacturer diligence checklist including facility registration and Form 483 history
• Quality and certification plan — TOTOX targets, CoA cadence, IFOS or equivalent timeline
• Regulatory pathway — separate US, UK and Canada tracks with the dose thresholds built in
• Unit economics model — per-bottle build from landed COGS through contribution to cohort payback
• Marketing and channel plan — DTC, Amazon, wholesale and subscription as four separate economic models
• Operations and inventory — MOQ-vs-shelf-life sizing worksheet
• Financial projections — 5-year P&L, cash flow and balance sheet with an oil-price sensitivity
• Funding request — structured for SBA 7(a), Start Up Loans or SEIS depending on your route
• Risk register — oxidation, quota and raw-material price, claim compliance, key-supplier concentration

The free version gives you the structure and the prompts. The $5 / £5 industry-specific template adds the worked examples, the pre-populated market data and the financial model. If you'd rather not write it, our research and content service handles the analysis and narrative, and the bespoke service delivers the whole plan with a five-year forecast. If your product line runs broader than EPA and DHA, the dietary supplements business plan template covers the wider category, and the food supplement manufacturer business plan template is the right starting point if you're building Model B rather than Model A.

Frequently Asked Questions